Intravitreal Dexamethasone Implant in Anti-Vascular Endothelial Growth Factor Pretreated Diabetic Macular Edema—A Swiss Cohort Study
In real-world clinical settings, the addition of DEX to anti-VEGF therapy in DME patients significantly reduces treatment burden and retinal fluid while maintaining visual function. Treatment decisions should balance anatomical and functional outcomes, considering individual patient needs.
Authors
- Ferhat Turgut (ORCID: https://orcid.org/0000-0002-8118-1610)
- Viviane Guignard
- Irmela Mantel (ORCID: https://orcid.org/0000-0002-8822-8194)
- Katja Hatz (ORCID: https://orcid.org/0000-0003-2807-0310)
- Christoph Tappeiner (ORCID: https://orcid.org/0000-0001-6907-1112)
- G. Donati
- Aude Ambresin (ORCID: https://orcid.org/0000-0002-6543-3400)
- Gábor Márk Somfai (ORCID: https://orcid.org/0000-0001-6329-442X)
- Dana Nagyová
- Isabel B. Pfister (ORCID: https://orcid.org/0000-0001-8752-8390)
- Justus G. Garweg (ORCID: https://orcid.org/0000-0003-3973-5082)
- Christine Schild
Institutions
- Semmelweis University (HU)
- University of Bern (CH)
- University of Basel (CH)
- University Hospital of Bern (CH)
- Hôpital Ophtalmique Jules-Gonin (CH)
- Berner Augenklinik am Lindenhofspital (CH)
- Hirslanden Clinique La Colline (CH)
- Vista Klinik (CH)
- Kantonsschule Olten (CH)
- Stadtspital Waid (CH)
- University of Duisburg-Essen (DE)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2024-09-19
- DOI
- https://doi.org/10.3390/ph17091235
- Citations
- 4
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.15